Skip to main
PYXS
PYXS logo

Pyxis Oncology (PYXS) Stock Forecast & Price Target

Pyxis Oncology (PYXS) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pyxis Oncology Inc. is actively involved in developing innovative therapeutics aimed at targeting challenging cancers, reflecting a strong commitment to improving patient quality of life. The company has promising potential revenue streams, including mid-to-high single-digit percent royalties from net sales in China, which are not yet factored into conservative forecasts. This indicates a potential for future revenue growth as the company advances its product candidates through clinical stages, positioning it favorably within the oncology market.

Bears say

Without the specific excerpts provided, a general analysis based on the description of Pyxis Oncology Inc can be outlined. Pyxis Oncology operates in a high-risk sector, with a focus on the development of next-generation therapeutics for challenging cancers; however, its preclinical status may present significant uncertainties regarding product efficacy and regulatory approval timelines. Furthermore, the company's financial position may be hampered by a lack of revenue generation, necessitating continued funding which could lead to dilution for existing shareholders. Lastly, the complexities involved in cancer therapeutics development could result in substantial cash burn and extended timeframes to reach potential commercialization, amplifying the overall investment risk associated with the stock.

Pyxis Oncology (PYXS) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pyxis Oncology and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pyxis Oncology (PYXS) Forecast

Analysts have given Pyxis Oncology (PYXS) a Buy based on their latest research and market trends.

According to 4 analysts, Pyxis Oncology (PYXS) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pyxis Oncology (PYXS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.